Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.51 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113786 | 0.89 | TGFBR1 (0.58) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL5107678 | 0.85 | MAPK14 (0.55) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL5108357 | 0.84 | MAPK14 (0.51) | MAPK14TGFBR1PRKD1KITMET | |
| SCHEMBL5107740 | 0.84 | TGFBR1 (0.54) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL14086503 | 0.82 | TGFBR1 (0.70) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL13998773 | 0.79 | TGFBR1 (0.75) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL13998759 | 0.79 | TGFBR1 (0.75) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL18428541 | 0.76 | TGFBR1 (0.72) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL5162700 | 0.76 | MAPK14 (0.51) | MAPK14TGFBR1KDRPRKD1PDGFRA | |
| SCHEMBL5102628 | 0.74 | TGFBR1 (0.59) | MAPK14TGFBR1KDRPRKD1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420685-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-16 | — | — | US | claimed |
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | claimed |
| US-8420685-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-8420685-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-8420685-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
| US-7407958-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2008-08-05 | — | — | US | disclosed |
| US-7407958-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319022-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ALK, ERBB4, ACVR1 | MAPK14 681/4885TGFBR1 55/4885KDR 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.